US 11,690,809 B2 · Method of treatment or alleviating symptoms of a disorder with cannabidiol

Abstract

A method of treating or alleviating symptoms of a disorder or a condition in a subject, including identifying the disorder or the condition of a subject, the disorder or condition identified based on first measures of a bloodstream concentration of a substance or a blood stream count of cellular elements, orally administering to said subject an amount of cannabidiol over a period of time effective treat or alleviate symptoms of said disorder or said condition, altering the bloodstream concentration of said substance or said blood stream count of cellular elements, and assessing efficacy of treating or alleviating symptoms of the disorder or the condition evidenced by comparing second measures of the bloodstream concentration of the substance or the blood stream count of cellular elements after the period time to the first measures of bloodstream concentration of the substance or the blood stream count of cellular elements.

Claims8

Dependent claims

A method of reducing fasting blood glucose level in a human subject, comprising

orally administering daily to said human subject in need thereof an effective amount of a composition comprising:
2 mg to 15 mg of cannabidiol liposome having a concentration of cannabidiol 10 mg/mL, <0.5% tetrahydrocannabinol, and <1 microS/cm water;
wherein said human subject has a fasting blood glucose level of 100 mg/dL to 141 mg/dL;
and
wherein said administering reduces said fasting bloodstream concentration of glucose of said human subject toward or to normative values.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

16/783,430Filed 6 Feb 2020

Published

US 2021/0244682 A112 Aug 2021

Granted

4 Jul 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/658
Medicinal preparations containing organic active ingredients: o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or…
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/1075
Emulsions ; Emulsion preconcentrates; Micelles: microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of…
A61K 9/127
Dispersions; Emulsions: synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Method of treatment or alleviating symptoms of a disorder with cannabidiol

Life of this patent

Method of treatment or alleviating symptoms of a disorder with cannabidiol

Life of this patent

Abstract

Claims8